Asthma Treatments

Find Asthma Treatments

Generic Name

Formoterol

Brand Names

Perforomist, Duaklir Pressair

FDA approval date: October 01, 2007

Classification: beta2-Adrenergic Agonist

Form: Powder, Solution

What is Perforomist (Formoterol)?

Formoterol fumarate inhalation solution is a long-acting beta 2 -adrenergic agonist indicated for: Long-term, twice daily administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease , including chronic bronchitis and emphysema.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous (SC) lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic trea...

Post-marketing Phase IV, Multicenter, Prospective Study to Observe the Safety and Tolerability of Breztri aerosphereTM Containing a Fixed Dose Combination of Budesonide 160 mcg/ Glycopyrronium 7.2 mcg/ Formoterol Fumarate Dehydrate 5 mcg in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Enrollment Status: Recruiting

Publish Date: March 18, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.

Phase I Study to Compare the Pharmacokinetics of Budesonide and Formoterol Delivered With Symbicort Aerosphere® and Symbicort® pMDI in Children 4 to Less Than 12 Years of Age With Asthma

Enrollment Status: Recruiting

Publish Date: March 12, 2026

Intervention Type: Combination product

Study Phase: Phase 1

Summary: The purpose of this study is to assess the pharmacokinetics (PK) and safety of symbicort aerosphere and symbicort pressurized metered dose inhaler (pMDI) in participants with asthma aged 4 to less than 12 years.

View All Clinical Trials